Press "Enter" to skip to content

FDA pulls up Aurobindo Pharma for ‘repeated’ failures in CGMP

The FDA recently issued a letter warning the drug- makers unit X1 in Srikakulam district of Andhra Pradesh for deviations from CGMP for API.

Original source:

Also Read:   J&J bumps up full-year profit view on strength of cancer drugs